Video Shorts

1:44
Exploring Frontline Outcomes With Ipilimumab/Nivolumab by Number of Doses in RCC
3 months ago
by
Sahil D. Doshi, MD

0:45
Phase 2 Trial Shows Efficacy of Pumitamig in Metastatic TNBC
3 months ago
by
Sarah Sammons, MD

0:44
Exploring ctDNA Dynamics in the IMvigor011 Trial
3 months ago
by
Thomas Powles, MD, MBBS, MRCP

0:53
Unpacking the Final Data From SunRISe-2
3 months ago
by
Andrea Necchi, MD

0:46
Top ASCO GU 2026 Abstracts According to Fellows
3 months ago
by
Riley Kandel

0:45
Imaging Modalities for Metastatic Breast Cancer Diagnosis and Staging
3 months ago
by
Igor Makhlin, MD

1:30
Rising Stars in GU Oncology Share New Data at OncLive Fellows Forum
3 months ago
by
Riley Kandel

1:25
Examining Alternative Splicing in Metastatic Bladder Cancer
3 months ago
by
Arshed Al-Obeidi, MD

0:52
Sarcomatoid vs Rhabdoid Dedifferentiation Outcomes in mccRCC
3 months ago
by
Akshit Chitkara, MD

0:57
The Exploration of Golcadomide in LBCL Management
3 months ago
by
Jason Westin, MD

0:59
Important Upcoming Clinical Trials to Watch For in MCL
3 months ago
by
Tycel Phillips, MD

0:57
Subcutaneous Blinatumomab Demonstrates Promising Efficacy and Safety in First Patient With MPAL
4 months ago
by
Ashkan Emadi, MD, PhD

2:36
Real-World Data for Luspatercept in Lower-Risk MDS
4 months ago
by
Amer Zeidan, MBBS, MD

0:47
Implications of the Negative VERONA Trial of Venetoclax/Azacitidine in Higher-Risk MDS
4 months ago
by
Guillermo Garcia-Manero, MD

0:41
First TTFields Approval in Pancreatic Cancer Paves Way for More Multimodal Approaches
4 months ago
by
Vincent J. Picozzi, MD

1:46
Understanding the Therapeutic Team Delivery Concept in Oncology
4 months ago
by
Maurie Markman, MD

0:59
Reexamining the Definition of Postpartum Breast Cancer
4 months ago
by
Lisa Zhang, MD

3:41
OncLive News Roundup for the Week of 2/15
4 months ago
by
Courtney Flaherty(+1 more)

1:35
Evolving Frontline Treatment Options in EGFR-Mutated NSCLC
4 months ago
by
Joel Neal, MD, PhD

1:41
Expert Insight on FDA Approval of T-DXd Plus Pertuzumab in HER2+ Breast Cancer
4 months ago
by
Riley Kandel

1:10
The Evaluation of CELMoDs in Multiple Myeloma
4 months ago
by
Sagar Lonial, MD, FACP, FASCO

0:49
Highlighting the Potential Implications of the Ongoing INAVO123 Trial in HR+ Breast Cancer
4 months ago
by
Reva K. Basho, MD

0:59
STELLAR-303 Paves the Way for Potential FDA Approval of Immunotherapy-Based Regimen in MSS CRC
4 months ago
by
Anwaar Saeed, MD

1:32
Deconstructing Clinical Trial Interpretation for Fellows
4 months ago
by
Matthew Hadfield, DO

0:23
Starving Breast Cancer of Copper to Stop Disease From Spreading
4 months ago
by
Linda Vahdat, MD, MBA

0:25
Highlighting the Role of Pathologists in Breast Cancer Care
4 months ago
by
David L. Rimm, MD, PhD

0:31
The Importance of Patient Selection for Breast Cancer Treatment Optimization
4 months ago
by
Vikram C. Gorantla, MD

1:10
Boosting Gender Equity in the Oncology Workforce
4 months ago
by
Ana Velázquez Mañana, MD, MSc, FASCO

1:42
Tracing the Evolution of Multidisciplinary Cancer Care
4 months ago
by
Maurie Markman, MD

1:10
Go Behind-the-Scenes With OncLive at TCT 2026
4 months ago
by
Courtney Flaherty
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5
